Summary
Six human glioma cell lines were established from tissues obtained from five patients diagnosed with Kernohan grade IV glioblastoma multiforme and one from a patient with a grade II astrocytoma. One line was from a recurrent patient who had received prior therapy; the other lines were derived from patients at initial diagnosis and/or before cytoreductive therapies other than surgery were given. Considerable variability in phenotypic, karyotypic, and cell surface marker expression was displayed between the six human glioma cell lines. The karyotypes ranged from apparently normal (grade II astrocytoma) to those with complex rearrangements. Trisomy of chromosome 7 was the most common abnormality. The extensive cytogenetic and molecular characterization of these lines may facilitate their utilization in cellular and molecular biologic studies.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albarosa, R.; Colombo, B. M.; Roz, L., et al. Deletion mapping of gliomas suggest the presence of two small regions for candidate tumor-suppressor genes in a 17-cM interval on chromosome 10q. Am. J. Hum. Genet. 58:1260–1267; 1996.
Albelda, S. M. Biology of disease: role of integrins and other cell adhesion molecules in tumor progression and metastasis. Lab. Invest. 68:4–15; 1993.
Ali-Osman, F.; Stein, D. E.; Renwick, A. Glutathione content and glutathione-S-transferase expression in 1,3-Bis(2-chloroethyl)-1-nitrosoureas-resistant human malignant astrocytoma cell lines. Cancer Res. 50:6976–6980; 1990.
Arai, K.; Horie, Y.; Kurimoto, M., et al. A cell line of human malignant astrocytoma producing autocrine growth factor. In Vitro Cell. Dev. Biol. 27A:606–614; 1991.
Bakir, A.; Gezen, F.; Fildiz, O., et al. Establishment and characterization of a human glioblastoma multiforme cell line. Cancer Genet. Cytogenet.; in press: 1998.
Bigner, D. D.; Bigner, S. H.; Ponten, J., et al. Heterogeneity of genotypic and phenotypic characteristics of fifteen permanent cell lines derived from human gliomas. J. Neuropathol. & Exp. Neurol. 40:201–229; 1981.
Bigner, S. H.; Mark, J.; Bigner, D. D. Cytogenetics of human brain tumors. Cancer Genet. Cytogenet. 47:141–154; 1990.
Bigner, S. H.; Mark, J.; Burger, P. C., et al. Specific chromosomal abnormalities in malignant human gliomas. Cancer Res. 48:405–411; 1988.
Bocchini, V.; Casalone, R.; Collini, P., et al. Changes in glial fibrillary acidic protein and karyotype during culturing of two cell lines established from human glioblastoma multiforme. Cell Tissue Res. 265:73–81; 1991.
Bodmer, S.; Strommer, K.; Frei, K., et al. Immunosuppression and transforming growth factor-β in glioblastoma. J. Immunol. 143:3222–3229; 1989.
Cordell, J. L.; Falini, B.; Erber, W. N., et al. Immunoenzymatic labeling of monoclonal antibodies using immune complexes of alkaline phosphatase and monoclonal anti-alkaline phosphatase (APAAP Complexes). J. Histochem. Cytochem. 32:219–229; 1984.
Dahl, D.; Ruegger, D. C.; Bigmami, A. Vimentin, the 57000 molecular weight of fibroblast filaments, is major cytoskeletal component in immature glia. Eur. J. Cell Biol. 24:191–196; 1981.
de Muralt, B.; de Tribolet, N.; Diserens, A.-C., et al. Phenotyping of 60 cultured human gliomas and 34 other neuroectodermal tumors by means of monoclonal antibodies against glioma, melanoma and HLA-DR antigens. Eur. J. Cancer & Clin. Oncol. 21:207–216; 1985.
Edelman, G. M. Cell adhesion molecules. Science 219:450–457; 1983.
Edelman, G. M. Cell adhesion molecules in neural histogenesis. Annu. Rev. Physiol. 48:417–430; 1986.
Fakhrai, H.; Dorigo, O.; Shawler, D. L., et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy. Proc. Natl. Acad. Sci. USA 93:2909–2914; 1996.
Figarella-Branger, D. F.; Durbec, P. L.; Rougon, G. N. Differential spectrum of expression of neural cell adhesion molecule isoforms and L1 adhesion molecules on human neuroectodermal tumors. Cancer Res. 50:6364–6370; 1990.
Fontana, A.; Hengartner, H.; deTribolet, N., et al. Glioblastoma cells release interleukins 1 and factors inhibiting interleukin 2-mediated effects. J. Immunol. 132:1837–1844; 1984.
Gately, C. L.; Muul, L. M.; Greenwood, M. A., et al. In vitro studies on the cell-mediated immune response to human brain tumors. II. Leukocyte-induced coats of glycosaminoglycan increase the resistance of glioma cells to cellular immune attack. J. Immunol. 133:3387–3395; 1984.
Gjerset, R. A.; Fakhrai, H.; Shawler, D. L., et al. Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway. In Vitro Cell. Dev. Biol. 31:207–214; 1995.
Heim, S.; Mitelman, F. Cancer cytogenetics. 2nd ed. New York: Wiley-Liss, Inc.; 1995:432–437.
Henn, W.; Blin, N.; Zang, K. D. Polysomy of chromosome 7 is correlated with overexpression of the erbB oncogene in human glioblastoma cell lines. Hum. Genet. 74:104–106; 1992.
Hermansson, M.; Nister, A.; Betsholtz, C., et al. Endothelial cell hyperplasia in human glioblastoma: coexpression of mRNA for platelet-derived growth factor (PDGF) B chain and PDGF receptor suggests autocrine growth stimulation. Proc. Natl. Acad. Sci. USA 85:7748–7752; 1988.
ISCN. Guidelines for cancer cytogenetics, an international system for human cytogenetic nomenclature. Mitelman, F., ed. Basel, Switzerland: S. Karger; 1995.
Kimmelman, A. C.; Ross, D. A.; Liang, B. C. Loss of heterozygosity of chromosome 10p in human gliomas. Genomics 34:250–254; 1996.
Kruse, C. A.; Mitchell, D. H.; DeMasters, B. K., et al. Characterization of an established human glioma cell line DBTRG-05MG: growth, kinetics, karyotype, receptor expression, and tumor suppressor gene analyses. In Vitro Cell. Dev. Biol. 28A:609–614; 1992.
Laws, E. R., Jr.; Thapar, K. Brain tumors. CA Cancer J. Clin. 43:263–271; 1993.
Liang, B. C. Evidence for association of mitochondrial DNA sequence amplification and nuclear localization in human low-grade gliomas. Mutat. Res. 354:27–33; 1996.
Liang, B. C.; Hays, L. Mitochondrial DNA copy number changes in human gliomas. Cancer Lett. 105:167–173; 1996.
Mauro, A.; Bulfone, A.; Turco, E., et al. Coexpression of platelet-derived growth factor (PDGF) B chain and PDGF B-type receptor in human gliomas. Child’s Nerv. Syst. 7:432–436; 1991.
Maxwell, M.; Naber, S. P.; Wolfe, H. J., et al. Expression of angiogenic growth factor genes in primary human astrocytomas may contribute to their growth and progression. Cancer Res. 51:1345–1351; 1991.
Naidu, A.; Wiranowska, M.; Kori, S. H., et al. Inhibition of human glioma cell proliferation and glutathione S-transferase by ascorbyl esters and interferon. Anticancer Res. 13:1469–1476; 1993.
Nister, M.; Claesson-Welsh, L.; Eriksson, A., et al. Differential expression of platelet derived growth factor receptors in human malignant glioma cell lines. J. Biol. Chem. 266:16755–16763; 1991.
Nister, M.; Libermann, T. A.; Betsholtz, C., et al. Expression of messenger RNAs for platelet-derived growth factor and transforming growth factor-α and their receptors in human malignant glioma cell lines. Cancer Res. 48:3910–3918; 1988.
Patel, K.; Bourne, S.; Coakham, H., et al. Expression of the neural cell adhesion molecule in human brain tumours. Biochem. Soc. Trans. 18:264; 1990.
Potapova, O.; Fakhrai, H.; Baird, S., et al. Platelet-derived growth factor-B/v-sis confers a tumorigenic and metastatic phenotype to human T98G glioblastoma cells. Cancer Res. 56:280–286; 1996.
Rasheed, B. K.; McLendon, R. E.; Friedman, H. S., et al. Chromosome 10 deletion mapping in human gliomas: a common deletion region in 10q25. Oncogene 10:2243–2246; 1995.
Rasheed, B. K.; McLendon, R. E.; Herndon, J. E., et al. Alteration of the TP53 gene in human gliomas. Cancer Res. 54:1324–1330; 1994.
Rey, J. A.; Bello, M. J.; deCampos, J. M., et al. Chromosomal patterns in human malignant astrocytomas. Cancer Genet. Cytogenet. 29:201–221; 1987.
Rutka, J. T.; Giblin, J. R.; Berens, M. E., et al. The effects of human recombinant tumor necrosis factor on glioma-derived cell lines: cellular proliferation, cytotoxicity, morphological and radioreceptor studies. Int. J. Cancer 41:573–582; 1988.
Schold, S. C.; Bullard, D. E.; Bigner, S. H., et al. Growth, morphology and serial transplantation of anaplastic human gliomas in athymic mice. J. Neuro-Oncol. 1:5–14; 1983.
Shapiro, J. R.; Shapiro, W. R. Therapy modifies cellular heterogeneity in human malignant gliomas. Adv. Oncol. 8:21–29; 1992.
Shapiro, J. R.; Yung, W.-K. A.: Shapiro, W. R. Isolation, karyotype, and clonal growth of heterogeneous subpopulations of human malignant gliomas. Cancer Res. 41:2349–2359; 1981.
Steck, P. A.; Gallick, G. E.; Maxwell, S. A., et al. Expression of epidermal growth factor receptor and associated glycoprotein on cultured human brain tumor cells. J. Cell. Biochem. 32:1–10; 1986.
Studer, A.; deTribolet, N.; Diserens, A., et al. Characterization of four human malignant glioma cell lines. Acta Neuropathol. (Berl.) 66:208–217; 1985.
Takeshita, L.; Sawa, H. Contrary effect of lactic acid on expression of neuron-specific enolase and glial fibrillary acidic protein in human glioma cells. Acta Neuropathol. 74:506–512; 1990.
Tallini, B.; Ladanyi, M.; Rosai, J., et al. Analysis of nuclear and mitochondrial DNA alterations in thyroid and renal oncocytic tumors. Cytogenet. Cell Genet. 66:253–259; 1994.
Ye, Z.; Qu, J. K.; Darras, B. T. Loss of heterozygosity for alleles on chromosome 10 in human brain tumours. Neurol. Res. 15:59–62; 1993.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kruse, C.A., Varella-Garcia, M., Kleinschmidt-Demasters, B.K. et al. Receptor expression, cytogenetic, and molecular analysis of six continuous human glioma cell lines. In Vitro Cell.Dev.Biol.-Animal 34, 455–462 (1998). https://doi.org/10.1007/s11626-998-0078-x
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/s11626-998-0078-x